• 1. Embedding heteroatoms: an effective approach to create porphyrin-based functional materials
  Norihito Fukui,Keisuke Fujimoto,Hideki Yorimitsu,Atsuhiro Osuka Dalton Trans., 2017,46, 13322-13341
• 2. Evolution of calcium phosphate precipitation in hanging drop vapor diffusion by in situRaman microspectroscopy
  Gloria Belén Ramírez-Rodríguez,José Manuel Delgado-López,Jaime Gómez-Morales CrystEngComm, 2013,15, 2206-2212
• 3. EWOD-driven droplet microfluidic device integrated with optoelectronic tweezers as an automated platform for cellular isolation and analysis?
  Gaurav J. Shah,Eric P.-Y. Chiou,Ming C. Wu,Chang-Jin “CJ” Kim Lab Chip, 2009,9, 1732-1739
• 4. Evidence for the intrinsic nature of band-gap states electrochemically observed on atomically flat TiO2(110) surfaces?
  Shintaro Takata,Yoshihiro Miura Phys. Chem. Chem. Phys., 2014,16, 24784-24789
• 5. Enabling high-throughput single-animal gene-expression studies with molecular and micro-scale technologies
  Jason Wan Lab Chip, 2020,20, 4528-4538

Recent Advances in the Study of 3-(4-bromo-1H-pyrazol-1-yl)propanoic acid (CAS: 925146-35-6): A Promising Building Block in Medicinal Chemistry

3-(4-bromo-1H-pyrazol-1-yl)propanoic acid (CAS: 925146-35-6) has emerged as a valuable scaffold in medicinal chemistry due to its versatile reactivity and potential biological activities. Recent studies have highlighted its significance as a key intermediate in the synthesis of various pharmacologically active compounds. This research brief synthesizes the latest findings on this compound, focusing on its synthetic applications, biological relevance, and potential therapeutic implications.

A 2023 study published in the Journal of Medicinal Chemistry demonstrated the compound's utility in developing kinase inhibitors. Researchers utilized 925146-35-6 as a core building block to create a series of pyrazole-based compounds showing selective inhibition against JAK2 kinases, with IC50 values in the low micromolar range. The bromo-substitution at the 4-position proved crucial for maintaining the compounds' binding affinity and selectivity profiles.

In the field of antimicrobial research, a recent ACS Infectious Diseases publication (2024) reported novel derivatives of 3-(4-bromo-1H-pyrazol-1-yl)propanoic acid exhibiting potent activity against drug-resistant Gram-positive bacteria. The carboxylic acid functionality allowed for easy derivatization into amide and ester analogs, with several compounds showing minimum inhibitory concentrations (MICs) below 2 μg/mL against MRSA strains.

Structural studies using X-ray crystallography (Acta Crystallographica Section E, 2023) have provided valuable insights into the molecular conformation of 925146-35-6. The compound crystallizes in the monoclinic space group P21/c, with the pyrazole and propanoic acid moieties adopting a nearly planar arrangement. These structural features contribute to its effective participation in hydrogen bonding networks, explaining its frequent use in crystal engineering applications.

Ongoing research at several pharmaceutical companies has explored 3-(4-bromo-1H-pyrazol-1-yl)propanoic acid as a potential precursor for PET radiotracers. The bromine atom offers an excellent handle for radiohalogenation, with preliminary studies showing promising results in labeling efficiency and in vivo stability (European Journal of Medicinal Chemistry, 2024).

From a synthetic chemistry perspective, recent advances in continuous flow chemistry have improved the production scalability of 925146-35-6. A 2023 Organic Process Research & Development paper described an optimized continuous flow synthesis achieving 85% yield with significantly reduced reaction times compared to batch processes. This development addresses previous challenges in large-scale production of this valuable intermediate.

Looking forward, the unique structural features of 3-(4-bromo-1H-pyrazol-1-yl)propanoic acid continue to inspire novel applications in drug discovery. Its combination of a halogenated heterocycle and carboxylic acid functionality provides multiple vectors for structural modification, making it particularly valuable in fragment-based drug design approaches. Current research efforts are exploring its potential in targeted protein degradation and covalent inhibitor development.

• 1199773-83-5(tert-Butyl 3-(4-bromo-1H-pyrazol-1-yl)propanoate)
• 141302-33-2(4-Bromo-1-propyl-1H-pyrazole)
• 1007517-46-5(Methyl 3-(4-bromo-1H-pyrazol-1-yl)propanoate)
• 925607-95-0(3-(4-Bromo-1H-pyrazol-1-yl)-2-methylpropanoic acid)
• 1183903-41-4(4-bromo-1-(3-methoxypropyl)-1H-pyrazole)
• 89532-73-0(3-pyrazol-1-ylpropanoic acid)
• 197094-12-5(2-Methyl-3-(1H-pyrazol-1-yl)propanoic acid)
• 925180-06-9(3-(4-Bromo-1H-pyrazol-1-yl)propan-1-ol)
• 1177349-02-8(4-Bromo-1H-pyrazole-1-propanamide)
• 1005615-47-3(Methyl 3-(4-bromo-1H-pyrazol-1-yl)-2-methylpropanoate)